{'fraction_non_alphanumeric': 0.020080321285140562, 'fraction_numerical': 0.005622489959839358, 'mean_word_length': 5.324873096446701, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Retrospective study on the correlation between 18‐fluorodeoxyglucose uptake in positron emission tomography–computer tomography and tumour volume, cytological activity as assessed with Ki‐67 and GLUT‐1 staining in 10 cases of Merkel cell carcinoma

been reported with different phenotypes, and in many cases, they have been confirmed by a positive patch test. Reactivity in the patch test both in ACD and non-immediate drug eruptions suggests that the culprit identified by the T cells in both reactions is either diltiazem or a metabolite formed both in the skin and after systemic metabolism. This example of diltiazem further strengthens the relation between ACD and T-cell-mediated drug reactions with SCD as one type of such systemic drug eruptions. Diltiazem is the only benzothiazepine derivative among all CCB. The others have either a phenylalkylamine structure or a dihydropyridine ring. Nevertheless, possible cross-reactions have been described, namely with verapamil, amlodipine and nifedipine. In our patient, no other CCB reacted. With this clinical case, the authors emphasize the possibility of the transrectal route for inducing SCD by local anaesthetics and specially by diltiazem, a drug seldom reported to cause ACD and SCD.